Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Longjintonglin Capsules is a Traditional Chinese Medicine (TCM) formulation primarily used for the treatment of chronic prostatitis, chronic pelvic pain syndrome (CPPS), and lower urinary tract symptoms (LUTS) associated with damp-heat syndrome. The capsule is composed of several herbal ingredients, including *Gentiana scabra* (Longdan), *Lonicera japonica* (Jinyinhua), *Paeonia lactiflora* (Chishao), and *Hedyotis diffusa* (Baihuaheshecao). Its pharmacological actions are characterized by clearing heat, detoxification, promoting diuresis to treat strangury, and resolving blood stasis to alleviate pain. In clinical practice, it is often evaluated for its ability to improve NIH-CPSI (National Institutes of Health Chronic Prostatitis Symptom Index) scores and urinary flow rates. The drug is approved in China and is manufactured by Yunnan Longrun Pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Longjintonglin Capsules.